close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

MDT

96.58

+0.01%↑

A

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

A

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

A

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

A

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

MDT

96.58

+0.01%↑

A

137.06

-0.07%↓

VEEV

224.89

+0.05%↑

HQY

91.67

-0.85%↓

PHR.US

16.88

-1.06%↓

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorHealthcare

7.28 1.11

Strong Buy

Price update 31 gru 2025, 18:53 UTC

BuySell

Overview

Share price change

24h

Current

Min

7.12

Max

7.37

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-3.82

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+88.42% upside

Market Stats

By TradingEconomics

Market Cap

22M

124M

Previous open

6.17

Previous close

7.28

News Sentiment

By Acuity

50%

50%

151 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

DJ

Read

30 gru 2025, 17:12 UTC

Major Market Movers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

DJ

Read

30 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

30 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

DJ

Read

30 gru 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

DJ

Read

30 gru 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

DJ

Read

30 gru 2025, 20:37 UTC

Earnings

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

DJ

Read

30 gru 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

DJ

Read

30 gru 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

DJ

Read

30 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

30 gru 2025, 16:20 UTC

Earnings

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

DJ

Read

30 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

DJ

Read

30 gru 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

DJ

Read

30 gru 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

DJ

Read

30 gru 2025, 15:10 UTC

Acquisitions, Mergers, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

DJ

Read

30 gru 2025, 14:24 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

DJ

Read

30 gru 2025, 14:22 UTC

Acquisitions, Mergers, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

DJ

Read

30 gru 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

DJ

Read

30 gru 2025, 14:17 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

DJ

Read

30 gru 2025, 14:16 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

DJ

Read

30 gru 2025, 14:14 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

DJ

Read

30 gru 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

DJ

Read

30 gru 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

LVMH Acquires Les Editions Croque Futur

DJ

Read

30 gru 2025, 13:49 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

DJ

Read

30 gru 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

DJ

Read

30 gru 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

DJ

Read

30 gru 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

DJ

Read

30 gru 2025, 11:55 UTC

Market Talk
Earnings

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

DJ

Read

30 gru 2025, 11:47 UTC

Earnings
Acquisitions, Mergers, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

DJ

Read

30 gru 2025, 11:35 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

88.42% upside

12 Months Forecast

Average 13.83 USD  88.42%

High 21 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

151 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

MDT

Medtronic PLC

96.58

↑ +0.01%

A

Agilent Technologies Inc

137.06

↓-0.07%

VEEV

Veeva Systems Inc

224.89

↑ +0.05%

HQY

HealthEquity Inc

91.67

↓-0.85%

PHR.US

Phreesia Inc

16.88

↓-1.06%
help-icon Live chat